Commentary

preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, Denise M Scholtens, Rohan Savoor, Bin Zhang, Jennifer D. Wu, Craig Michael Horbinski, Rimas Vincas Lukas, David C. Binder, Derek Alan Wainwright*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.

Original languageEnglish (US)
Article number1548242
JournalOncoImmunology
Volume8
Issue number3
DOIs
StatePublished - Mar 4 2019

Fingerprint

Glioblastoma
Biomarkers
Computational Biology
Gene Expression

Keywords

  • IDO
  • Treg
  • brain tumor
  • glioblastoma
  • immunosuppression
  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

@article{62dd6ea27ea540a2b0b96845a84ce77d,
title = "Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)",
abstract = "Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.",
keywords = "IDO, Treg, brain tumor, glioblastoma, immunosuppression, immunotherapy",
author = "Lijie Zhai and Erik Ladomersky and Lauing, {Kristen L.} and Meijing Wu and Scholtens, {Denise M} and Rohan Savoor and Bin Zhang and Wu, {Jennifer D.} and Horbinski, {Craig Michael} and Lukas, {Rimas Vincas} and Binder, {David C.} and Wainwright, {Derek Alan}",
year = "2019",
month = "3",
day = "4",
doi = "10.1080/2162402X.2018.1548242",
language = "English (US)",
volume = "8",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "3",

}

Commentary : preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017). / Zhai, Lijie; Ladomersky, Erik; Lauing, Kristen L.; Wu, Meijing; Scholtens, Denise M; Savoor, Rohan; Zhang, Bin; Wu, Jennifer D.; Horbinski, Craig Michael; Lukas, Rimas Vincas; Binder, David C.; Wainwright, Derek Alan.

In: OncoImmunology, Vol. 8, No. 3, 1548242, 04.03.2019.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Commentary

T2 - preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

AU - Zhai, Lijie

AU - Ladomersky, Erik

AU - Lauing, Kristen L.

AU - Wu, Meijing

AU - Scholtens, Denise M

AU - Savoor, Rohan

AU - Zhang, Bin

AU - Wu, Jennifer D.

AU - Horbinski, Craig Michael

AU - Lukas, Rimas Vincas

AU - Binder, David C.

AU - Wainwright, Derek Alan

PY - 2019/3/4

Y1 - 2019/3/4

N2 - Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.

AB - Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.

KW - IDO

KW - Treg

KW - brain tumor

KW - glioblastoma

KW - immunosuppression

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85058708960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058708960&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1548242

DO - 10.1080/2162402X.2018.1548242

M3 - Comment/debate

VL - 8

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 3

M1 - 1548242

ER -